Effects of Pemafibrate on Serum Carnitine and Plasma Myostatin in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease DOI Creative Commons
Ryohei Tanigawa, Atsushi Nakajima, Yuichiro Eguchi

et al.

Deleted Journal, Journal Year: 2025, Volume and Issue: 8(1)

Published: Jan. 1, 2025

ABSTRACT Background Pemafibrate, a selective peroxisome proliferator‐activated receptor alpha (PPARα) modulator (SPPARMα), has positive effects on liver‐related markers (e.g., liver stiffness determined by magnetic resonance elastography and alanine aminotransferase) in the PEMA‐FL study patients with metabolic dysfunction‐associated steatotic disease (MASLD). Patients MASLD reportedly have high rate of muscle mass loss; hence, prevention treatment sarcopenia is important for MASLD. PPARα may be involved expression carnitine myostatin, which are known muscle‐related markers. We conducted post‐hoc analysis to investigate pemafibrate myostatin levels. Methods The study, double‐blind, placebo‐controlled, randomized, multicenter, Phase 2 trial, randomized 118 either Pemafibrate 0.4 mg/day or placebo (1:1) group (orally, twice daily 72 weeks). This examined percentage change total carnitine, free acylcarnitine, compared those group. correlation between changes Results Pmafibrate significantly increased serum levels from baseline at Week 48 (treatment difference 24.2%; p < 0.001, 27.3%; respectively) similar trends acylcarnitine 10.7%). reduced plasma −11.0%; 0.01) baseline. Analysis significant subgroups showed almost all subgroups. percent 12 weeks demonstrated no obvious correlations ( r = 0.337, 0.358, 0.077, respectively). Conclusions decreased MASLD, potential application development progression sarcopenia, but there results effect mass. Further research warranted determine whether these physiology can lead clinical benefits Trial Registration: ClinicalTrials.gov identifier: NCT03350165.

Language: Английский

Da NAFLD a MASLD: pillole per endocrinologi DOI
Vincenza Di Stasi, Elisa Maseroli, Giovanni De Pergola

et al.

L Endocrinologo, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 10, 2025

Citations

0
Lean MASLD and IBD: Exploring the Intersection of Metabolic Dysfunction and the Gut–Liver Axis DOI Creative Commons
Adrian Rotaru, Remus Stafie, Ermina Stratina

et al.

Life, Journal Year: 2025, Volume and Issue: 15(2), P. 288 - 288

Published: Feb. 12, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) challenges traditional paradigms by manifesting in lean individuals. The link between MASLD and inflammatory bowel (IBD) underscores the importance of gut-liver axis progression chronic inflammation. This study evaluates prevalence, clinical characteristics, diagnostic predictors individuals with without IBD. prospective included 387 patients. Hepatic steatosis fibrosis were assessed using vibration-controlled transient elastography (VCTE). Anthropometric, biological data compared. subgroup analyses focused on patients was present 34.1% 46.3% those who had increased visceral adiposity (CUN-BAE: 31.21 ± 5.42 vs. 24.57 6.49, p < 0.001) metabolic dysfunction, including dyslipidemia elevated fasting glucose. IBD-MASLD exhibited greater hepatic systemic CUN-BAE outperformed FLI HSI predicting steatosis, especially IBD (AUC = 0.806). Lean MASLD, particularly patients, highlights need for tailored management strategies. plays a key role progression, index demonstrates superior accuracy identifying steatosis.

Language: Английский

Citations

0
Prognostic and predictive effects of new steatotic liver disease nomenclatures: a large population‐based study DOI Creative Commons

Huixian Zeng,

Letian Fang,

Zhiyu Yang

et al.

MedComm, Journal Year: 2025, Volume and Issue: 6(2)

Published: Feb. 1, 2025

Abstract We aimed to compare the association of metabolic dysfunction‐associated fatty liver disease (MAFLD), steatotic (MASLD), alcohol‐related (ALD), dysfunction and ALD (MetALD), MASLD with viral hepatitis (MASLD‐Viral) risks cirrhosis, cancer, mortality. The data 464,556 adults from UK Biobank (UKB), 13,526 National Health Nutrition Examination Survey (NHANES), 2554 BeijngFH Cohort Study (FHCS) were included. Adjusted hazard ratios (aHR) odds calculated using Cox Logistic regression models, respectively. Compared non‐SLD, risk cancer increased MetALD (aHR 1.70 [95% CI 1.37, 2.09]), (1.91 [1.66, 2.21]), MAFLD (2.01 [1.76, 2.29]), (3.16 [2.54, 3.93]), MASLD‐Viral (22.0 [10.8, 44.4]) in a stepwise manner UKB; all‐cause mortality MetALD, MASLD, MAFLD, ALD, NHANES. ratio fibrosis FHCS. In patients diabetes, metformin plus other drugs associated higher or MAFLD. Prevention rather than antiglycemic treatment is important for diabetic

Language: Английский

Citations

0
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management DOI Creative Commons
Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi

et al.

Exploration of Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 17, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging and rapidly growing health problem that currently affects more than one-third of the world general population two-thirds patients with obesity or type 2 diabetes. MASLD associated one cardio-metabolic risk factors (CMRFs) determine complexity its natural history management. Although term encompasses a single disease, each CMRF has different impact on MASLD, number overlapping CMRFs results in rate progression outcomes both systemic disease. Its pathogenesis characterized by insulin resistance, lipotoxicity complex cross-talk between liver, adipose tissue, muscle, intestine through release hepatokines, cytokines, myokines inflammatory products. The stage fibrosis best predictor outcomes, such as failure mortality, also predicts high all-cause mortality In many cases, development hepatocellular carcinoma (HCC) advanced cirrhosis, although it can occur at all stages making prevention difficult. increasing very low-density lipoprotein (VLDL) secretion chronic low-grade inflammation, which increase cardio-vascular, renal, endocrine diseases extrahepatic cancer. Thus, management requires holistic approach treatment multispecialty collaboration. Currently, diet physical activity are effective first-line approaches. There no approved drugs for apart from resmetirom, percentage cases improves metabolic steatohepatitis (MASH) fibrosis. We summarize wide varied recent literature etiopathogenetic, clinical therapeutic aspects connecting interpreting to facilitate

Language: Английский

Citations

0
Highlights of the Most Recent American Diabetes Association Guidelines: From Evidence to Practice DOI Creative Commons
Mee Kyoung Kim

Endocrinology and Metabolism, Journal Year: 2025, Volume and Issue: 40(1), P. 67 - 69

Published: Feb. 25, 2025

Language: Английский

Citations

0
Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease DOI Creative Commons
Sang Yoon Lee,

Su-Been Lee,

Goo-Hyun Kwon

et al.

The Journal of Microbiology, Journal Year: 2025, Volume and Issue: 63(2), P. e2411002 - e2411002

Published: Feb. 27, 2025

Language: Английский

Citations

0
Artificial Intelligence‐Based Diets: A Role in the Nutritional Treatment of Metabolic Dysfunction‐Associated Steatotic Liver Disease? DOI
Tuğçe ÖZLÜ, Emre Batuhan Kenger, Yusuf Yılmaz

et al.

Journal of Human Nutrition and Dietetics, Journal Year: 2025, Volume and Issue: 38(2)

Published: Feb. 27, 2025

ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a growing global health concern. Effective management of this condition relies heavily on lifestyle modifications and dietary interventions. In study, we sought to evaluate the plans for MASLD generated by ChatGPT (GPT‐4o) according current guideline recommendations. Methods was used create single‐day meal 48 simulated patients with MASLD, tailored individual characteristics such as age, gender, height, weight transient elastography parameters. The were assessed appropriateness disease‐specific guidelines. Results mean energy content menus planned 1596.9 ± 141.5 kcal accuracy 91.3 11.0%, fibre 22.0 0.6 g 88.1 2.5%. However, they exhibited elevated levels protein, fat saturated acids. Conversely, carbohydrate lower. recommended loss obese but did not extend advice normal‐weight overweight individuals. Notably, recommendations Mediterranean diet physical activity absent. Conclusions shows potential in developing management. discrepancies macronutrient distributions omission key evidence‐based highlight need further refinement. To enhance effectiveness AI tools recommendations, alignment established guidelines must be improved.

Language: Английский

Citations

0
Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging Pathogenic Mechanisms and Therapeutic Implications DOI Creative Commons
Farah Abdelhameed, A.I. Mustafa, Chris Kite

et al.

Livers, Journal Year: 2025, Volume and Issue: 5(1), P. 11 - 11

Published: March 4, 2025

Non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated steatotic (MASLD), is the most common cause of chronic worldwide. Characterized by excessive hepatic fat accumulation, this encompasses a spectrum from simple steatosis to more severe forms, including steatohepatitis, fibrosis, and cirrhosis. Emerging evidence highlights pivotal role gut dysbiosis in pathogenesis MASLD. Dysbiosis disrupts gut–liver axis, an intricate communication network that regulates metabolic, immune, barrier functions. Alterations microbiota composition, increased permeability, translocation pro-inflammatory metabolites/factors have been shown trigger inflammatory fibrotic cascades, exacerbating inflammation injury. Recent studies identified microbiome signatures associated with MASLD, offering promise non-invasive diagnostic biomarkers paving way for new potential therapeutic strategies targeting dysbiosis. This review explores crucial MASLD need further targeted research field validate microbial optimize strategies. Comprehensive understanding axis may enable innovative approaches, transforming clinical management

Language: Английский

Citations

0
From NAFLD to MASLD: transforming steatotic liver disease diagnosis and management DOI Open Access
Paula Iruzubieta, Carolina Jiménez-González, Joaquín Cabezas

et al.

Metabolism and Target Organ Damage, Journal Year: 2025, Volume and Issue: 5(1)

Published: March 8, 2025

The transition from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic (MASLD) represents a significant evolution in the nomenclature of disease. This updated terminology emphasizes dysfunction as central criterion, offering greater precision and improved risk stratification. MASLD broadens scope classification by incorporating individuals with diverse profiles, including lean patients hepatic steatosis, aligns clinical practice multifactorial nature this condition. global adoption creates opportunities for standardization research settings, facilitating multicenter collaborations enhancing development diagnostic tools therapeutic strategies. However, new poses challenges, potential confusion during implementation, cultural linguistic barriers, integration MetALD, need educational initiatives targeting healthcare providers patients. Further efforts are required refine criteria, address implementation seamlessly incorporate into international coding systems. review evaluates key advantages ongoing challenges associated MASLD, providing comprehensive analysis its impact on practice, research, health

Language: Английский

Citations

0
Flaxseed-derived peptide, Ile-Pro-Pro-Phe (IPPF), ameliorates hepatic cholesterol metabolism to treat metabolic dysfunction-associated steatotic liver disease by promoting cholesterol conversion and excretion DOI
Xingyu Yuan, Yifeng Hou, Nan Qin

et al.

Food & Function, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

IPPF ameliorates hepatic cholesterol metabolism to treat MASLD.

Language: Английский

Citations

0